We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

300 Antibodies Generated That Have Neutralization Potential Against SARS-CoV-2

Product News   May 20, 2020

 
300 Antibodies Generated That Have Neutralization Potential Against SARS-CoV-2

Human immune cells in a synthetic lymph node produced by Prellis Biologics. Credit: Prellis Biologics, Inc.

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Aigenpulse Introduces Novel Data Intelligence Platform to Expedite Drug Discovery and Development

Product News

Aigenpulse has introduced a new state-of-the-art data intelligence platform that is designed to expedite the drug discovery and development process.

READ MORE

New Partnership To Provide Synthetic Nanobodies Against SARS-CoV-2 Receptor Binding Domain

Product News

Absolute Antibody Ltd. has announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain of SARS-CoV-2.

READ MORE

Cancer Research UK and Abcam Launch Custom Antibody Partnership to Accelerate Research

Product News

Cancer Research UK and Abcam plc have announced a new partnership for the development and commercialization of novel custom antibodies to support the acceleration of cancer research.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE